Clinical Trial Update: Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of Paxalisib (GDC-0084) for recurrent or refractory primary central nervous system lymphoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Paxalisib (GDC-0084)

Snippet

Sponsor: Lakshmi Nayak, MD | Conditions: Primary Central Nervous System Lymphoma, Non-Hodgkin Lymphoma of Extranodal Site | Phase 2 | Status: RECRUITING